Handbook of Clinical medicine

is only as reliable as a person’s last test) and failure to disclose. It does not consider transfer of treatment resistance, other STIs, or hepatitis. Post-exposure prophylaxis (PEP): The short-term use of antiretroviral therapy (ART) after potential HIV exposure (sexual or occupational) should be considered an emer- gency method of HIV prevention. Can be given up to 72h (ideally <24h) after exposure. Not recommended if exposure is to a person on ART with a confi rmed and sustained (>6 months) undetectable (<200 copies/mL) viral load. 1st-line PEP6 in UK is Truvada® (tenofovir/emtricitabine) and raltegravir for 28 days (2015) (refer to local guidelines). Test for HIV 8–12 weeks after exposure. Pre-exposure prophylaxis (PrEP): The use of ART in those at high risk of acquiring HIV including serodiff erent relationships without suppression of viral load, condomless anal sex in MSM. Trials (PROUD, IPERGAY) show an 86% reduction in HIV incidence. A large scale trial of PrEP provision (2017–2020) will inform future NHS funding decisions. Vertical transmission: All pregnant women with HIV should have commenced ART by 24 weeks’ gestation. Caesarean delivery indicated if viral load >50 copies/mL. Neonatal PEP is given from birth to 4wks old with formula-feeding. __OOHHCCMM__1100ee..iinnddbb 339988 0022//0055//22001177 1199::0077
